NCT05378906View on ClinicalTrials.gov

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

September 28, 2022

Study Completion Date

September 28, 2022

Conditions
Healthy
Interventions
DRUG

DRV/COBI FDC

Participants will receive a single oral dose of DRV/COBI FDC tablet dispersed in water as per assigned treatment sequence.

DRUG

COBI

Participants will receive a single oral dose of COBI tablet as per assigned treatment sequence.

DRUG

DRV

Participants will receive single oral dose of DRV suspension as per the assigned treatment sequence.

Trial Locations (1)

2650

SGS Belgium NV, Edegem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY